ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(01541.HK) 가격

ImmuneOnco Biopharmaceuticals (Shanghai), Inc. operates as an early-stage biopharmaceutical company which develops and commercializes novel cancer immunotherapeutic products. The company is headquartered in Shanghai, Shanghai and currently employs 195 full-time employees. The company went IPO on 2023-09-05. The firm's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The firm's core product IMM01 is an innovative CD47-targeted molecule. The firm mainly operates its businesses in the domestic and overseas markets.